BioNTech Q3 2026 swings to net profit of €184.5 million
BNTX•BioNTech reported third-quarter 2026 net profit of €184.5 million, compared with a loss of €28.7 million a year earlier. Revenue fell 15% to €1.29 billion, while research and development expenses rose 32% to €748.1 million.
1. Quarterly results
BioNTech swung to a third-quarter 2026 net profit of €184.5 million from a year-earlier loss of €28.7 million. Revenue declined 15% year over year to €1.29 billion due to lower demand for COVID-19 vaccines, while research and development expenses increased 32% to €748.1 million, driven by late-stage oncology development costs and intangible-asset impairments. A planned global Phase 3 trial will evaluate pumitamig with Gilead’s sacituzumab govitecan in triple-negative breast cancer, pending regulatory approval.
